Similar results were found for investigating EZH2 overexpression on overall survival of stage I NSCLC patients (a Begg’s test score of p = 0.774 and an Egger’s test score of p = 0.221) (Fig. 4). This evidence concerns the gene EZH2 and non-small cell lung carcinoma.